Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose spironolactone vs finerenone for albuminuria in type 2 diabetes
jRCTs031240068Recruiting
- Start
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial in type 2 diabetes mellitus (T2DM) and diabetic glomerulosclerosis comparing Low-dose spironolactone with Finerenone (2 arms). Started May 2024; status: recruiting.
02
Drugs
spironolactonefinerenone
03
Conditions
type 2 diabetes mellitus (T2DM)diabetic glomerulosclerosis
Beyond the preview
Go deeper on jRCTs031240068.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031240068.